Skip to main content

PhosSTOP phosphatase inhibitor tablets

Composition
Phosphatase inhibitor tablets

References

  1. The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease (2023). https://doi.org/10.1186/s13024-023-00632-5 Methods: "8830) and PhosSTOP phosphatase inhibitors (Sigma-Aldrich Pty Ltd Cat#4906845001). Hippocampal tissue was then homogenised by low amplitude" · DOI: 10.1186/s13024-023-00632-5
  2. The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis (2025). https://doi.org/10.26508/lsa.202403080 Methods: "tection of phospho-Syk, the lysis buffer contained PhosSTOP reagent (4906845001; Sigma-Aldrich). All blocking and washing steps were perfor" · DOI: 10.26508/lsa.202403080
  3. Microglial CLEC7A restrains amyloid beta plaque pathology in a mouse model of Alzheimer's disease (2025). https://doi.org/10.1002/alz.70943 Methods: "d 1:8 in 1x DPBS with PhosSTOP phosphatase inhibitors (Sigma-Aldrich #4906845001) and cOmplete protease inhibitors (Sigma-Aldrich #116974980" · DOI: 10.1002/alz.70943

Listed SKUs

Reference, supply and purchase path

No verified catalog mapping exists for this reagent; reference status: unknown.

Bulk pricing and availability inquiry

Submitting an inquiry does not place an order or confirm a purchase.

No exact merchant mapping is verified for this reagent; the reference below is an internal inquiry identifier only.

Reagent:PhosSTOP phosphatase inhibitor tablets

Stable id:reagent-655(Internal inquiry reference (site id; not a merchant catalog or manufacturer SKU))

Specification: unknown (not verified)